logo
welcome
Investor's Business Daily

Investor's Business Daily

Novo Nordisk's weight-loss drug misses expectations in late-stage trial

Investor's Business Daily
Summary
Nutrition label

73% Informative

Danish pharmaceutical giant Novo Nordisk's weight-loss drug CagriSegma missed expectations in a late-stage trial.

Novo 's setback was good news for Eli Lilly , Viking Therapeutics and Amgen .

Eli Lilly stock leapt 6% before the open, while Amgen also rose.

VR Score

69

Informative language

72

Neutral language

14

Article tone

formal

Language

English

Language complexity

46

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links